Multiple myeloma: open trials in Japan

34 open trials have a site in Japan. Registry data; only the trial team decides who can take part.

NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Yamanashi Prefectural Central Hospital, Kofu · National Hospital Organization Matsumoto Medical Center, Matsumoto-shi · Nagoya City University Hospital, Nagoya · National Hospital Organization Okayama Medical Center, Okayama · Tokushima Prefectural Central Hospital, Tokushima
Registry updated 2026-11-04
NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Kameda Medical Center, Chiba · Fukuoka University Hospital, Fukuoka · Ogaki Municipal Hospital, Gifu · Teine Keijinkai Hospital, Hokkaido · Kobe City Medical Center General Hospital, Kobe · Dokkyo Medical University Saitama Medical Center, Koshigaya · Kumamoto University Hospital, Kumamoto · Kurashiki Central Hospital, Kurashiki · National Hospital Organization Matsumoto Medical Center, Matsumoto · National Hospital Organization Okayama Medical Center, Okayama · Japanese Red Cross Osaka Hospital, Osaka · National Hospital Organization Hiroshima-Nishi Medical Center, Ōtake · Iwate Medical University Hospital, Shiwa-gun
Registry updated 2026-11-03
NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Trial Treatment · Phase 4 · Janssen Research & Development, LLC
Nagoya City University Hospital, Nagoya · Japanese Red Cross Medical Center, Shibuya City
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Juntendo University Hospital, Bunkyō City · Kameda Medical Center, Chiba · Chiba Cancer Center, Chiba · National Hospital Organization Mito Medical Center, Higashiibaraki-gun · Kansai Medical University Hospital, Hirakata · Hyogo Medical University Hospital, Hyōgo · Saitama Medical University Hospital, Iruma-gun · Tokai University Hospital, Kanagawa · Kanazawa University Hospital, Kanazawa · Kumamoto University Hospital, Kumamoto · Matsuyama Red Cross Hospital, Matsuyama · National Hospital Organization Nagasaki Medical Center, Nagasaki · National Hospital Organization Okayama Medical Center, Okayama · Osaka Metropolitan University Hospital, Osaka · National Hospital Organization Hokkaido Cancer Center, Sapporo · National Hospital Organization Shibukawa Medical Center, Shibukawa · Japanese Red Cross Medical Center, Shibuya-ku · Shizuoka Cancer Center, Sunto-gun · Fujita Health University Hospital, Toyoake · Yamagata University Hospital, Yamagata · Yamanashi Prefectural Central Hospital, Yamanashi
Registry updated 2026-11-03
NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Japanese Red Cross Medical Center, Shibuya City · Osaka University Hospital, Suita-shi · The Cancer Institute Hospital of JFCR, Tokyo
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyō City · Chiba Cancer Center, Chiba · Shonan Kamakura General Hospital, Kamakura-shi · Kameda Medical Center, Kamogawa · Yamanashi Prefectural Central Hospital, Kofu · The Jikei University Hospital, Minato · Japanese Red Cross Medical Center, Shibuya City · Kanagawa Cancer Center, Yokohama
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Chiba · Fukuoka · Fukuoka · Higashiibaraki · Hiroshima · Iruma · Kamakura · Kashiwa · Kitakyushu-shi · Koshigaya · Kumamoto · Nagaizumi-cho,Sunto-gun · Nagasaki · Sapporo · Shibuya-ku · Shiwa-gun Yahaba-cho · tabashi City · Tokyo
Registry updated 2026-10-30
NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · AstraZeneca
Kashiwa · Nagoya · Yamagata
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Kyushu University Hospital, Fukuoka · Kanazawa University Hospital, Kanazawa · National Cancer Center Hospital East, Kashiwa · Kumamoto University Hospital, Kumamoto · Nagoya City University Hospital, Nagoya · Hyogo Medical University Hospital, Nishinomiya · National Hospital Organization Okayama Medical Center, Okayama · Osaka Red Cross Hospital, Osaka · Japanese Red Cross Medical Center, Shibuya-ku · Yamagata University Hospital, Yamagata
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Kyushu University Hospital, Fukuoka · Gunma University Hospital, Maebashi · Shizuoka Cancer Center, Nagaizumi-chō · National Hospital Organization Okayama Medical Center, Okayama · Osaka Metropolitan University Hospital, Osaka · Tohoku University Hospital, Sendai · Japanese Red Cross Medical Center, Shibuya-ku · Iwate Medical University Hospital, Yahaba-cho · Yamagata University Hospital, Yamagata · University of Fukui Hospital, Yoshida-gun
Registry updated 2026-10-27
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
University Hospital Kyoto Prefectural University of Medicine /ID# 271911, Kyoto · Nagoya City University Hospital /ID# 271427, Nagoya · Japanese Red Cross Medical Center /ID# 272018, Shibuya-ku · The University of Osaka Hospital /ID# 271636, Suita-shi · The Jikei University Hospital /ID# 272091, Tokyo
Registry updated 2026-10-27
NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
Saitama Medical University International Medical Center, Hidaka · Ibaraki Prefectural Central Hospital, Kasama-Shi · National Cancer Center Hospital East, Kashiwa-shi · University Hospital, Kyoto Prefectural Univ of Medicine, Kyoto · Gunma University Hospital, Maebashi · Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya · Nagoya City University Hospital, Nagoya · Japanese Red Cross Medical Center, Shibuya-ku · Tokushima Prefectural Central Hospital, Tokushima · Keio University Hospital, Tokyo
Registry updated 2026-10-26
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Nagoya
Registry updated 2026-10-21
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
Nagoya City University Hospital, Aichi · National Hospital Organization Okayama Medical Center, Okayama · The Cancer Institute Hospital of JFCR, Tokyo · Yamagata University Hospital, Yamagata
Registry updated 2026-10-20
NCT07409246
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1 · AbbVie
Tokyo Metropolitan Komagome Hospital /ID# 279070, Bunkyo Ku · The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 279069, Koto-ku
Registry updated 2026-10-20
NCT06892522
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Trial Treatment · Phase 1/2 · AbbVie
University Hospital Kyoto Prefectural University of Medicine /ID# 275713, Kyoto · Nagoya City University Hospital /ID# 273529, Nagoya · Japanese Red Cross Medical Center /ID# 273530, Shibuya-ku · The University of Osaka Hospital /ID# 275791, Suita-shi
Registry updated 2026-10-19
NCT07095452
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Trial Treatment · Phase 2/3 · AbbVie
Tokai University Hospital /ID# 278157, Isehara · Kurume University Hospital /ID# 278209, Kurume-shi · University Hospital Kyoto Prefectural University of Medicine /ID# 278156, Kyoto · Matsuyama Red Cross Hospital /ID# 278660, Matsuyama · Nagoya City University Hospital /ID# 278188, Nagoya
Registry updated 2026-10-19
NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Trial Treatment · Phase 2 · Sanofi
Okayama
Registry updated 2026-10-15
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Nagoya City University Hospital, Aichi · Matsuyama Red Cross Hospital, Ehime · Gunma University Hospital, Gunma · Hyogo Medical University Hospital, Hyōgo · University Hospital Kyoto Prefectural University of Medicine, Kyoto · Iwate Medical University Hospital, Numakunai · National Hospital Organization Okayama Medical Center, Okayama · Osaka University Hospital, Osaka · Dokkyo Medical University Saitama Medical Center, Saitama · Japanese Red Cross Medical Center, Shibuya-ku · The Cancer Institute Hospital of JFCR, Tokyo · Toyohashi Municipal Hospital, Toyohashi · Yamagata University Hospital, Yamagata
Registry updated 2026-10-13
NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Chiba Cancer Center, Chiba · Fukushima Medical University, Fukushima · Saitama Medical University Hospital, Iruma-gun · Kameda General Hospital, Kamogawa · National Cancer Center Hospital East, Kashiwa-shi · National Hospital Organization Okayama Medical Center, Kita-ku · Yamanashi Prefectural Central Hospital, Kofu · National Hospital Organization Kumamoto Medical Center, Kumamoto · Kurume University Hospital, Kurume · Gunma University Hospital, Maebashi · Aichi Medial University Hospital, Nagakute · Ogaki Municipal Hospital, Ōgaki · Sapporo Hokuyu Hospital, Sapporo · National Hospital Organization Sendai Medical Center, Sendai · NHO Shibukawa Medical Center, Shibukawa · Japanese Red Cross Medical Center, Shibuya-ku · Iwate Medical University Hospital, Shiwa-gun · Osaka University Hospital, Suita-shi · Tokushima Prefectural Central Hospital, Tokushima
Registry updated 2026-10-07
NCT06297226
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Chiba University Hospital, Chiba · University Hospital Kyoto Prefectural University of Medicine, Kyoto · Nagoya City University Hospital, Nagoya · Hyogo Medical University Hospital, Nishinomiya · Japanese Red Cross Medical Center, Shibuya-ku
Registry updated 2026-10-06
NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Trial Treatment · Phase 3 · AstraZeneca
Bunkyō City · Kashiwa · Kyoto · Nagoya · Shibuya-ku · Shinjuku-ku
Registry updated 2026-09-29
NCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Chiba Cancer Center, Chiba · National Hospital Organization Kyushu Medical Center, Fukuoka · Gunma University Hospital, Gunma · Shonan Kamakura General Hospital, Kamakura-shi · University Hospital Kyoto Prefectural University of Medicine, Kyoto · Matsuyama Red Cross Hospital, Matsuyama · National Hospital Organization Okayama Medical Center, Okayama · Sapporo City General Hospital, Sapporo · The Cancer Institute Hospital of JFCR, Tokyo · Kanagawa Cancer Center, Yokohama
Registry updated 2026-09-25
NCT07227311
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 2 · GlaxoSmithKline
Aichi · Chiba · Ehime · Fukushima · Gunma · Hokkaido · Ishikawa · Numakunai · Okayama · Osaka · Sendai · Tokyo · Yamanashi
Registry updated 2026-08-25
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Akita University Hospital, Akita · National Hospital Organization Kyushu Cancer Center, Fukuoka · Kagoshima University Hospital, Kagoshima · National Hospital Organization Kumamoto Medical Center, Kumamoto · Nagasaki University Hospital, Nagasaki · Nagoya City University Hospital, Nagoya · National Hospital Organization Okayama Medical Center, Okayama · Osaka Metropolitan University Hospital, Osaka · Tohoku University Hospital, Sendai · National Hospital Organization Shibukawa Medical Center, Shibukawa · Japanese Red Cross Medical Center, Shibuya-ku · Shizuoka Cancer Center, Sunto-gun · Tokushima University Hospital, Tokushima · Iwate Medical University Hospital, Yahaba-cho · Yamagata University Hospital, Yamagata · University of Fukui Hospital, Yoshida-gun
Registry updated 2026-08-24

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error